Facilitated By

San Antonio Medical Foundation

A Phase III, Randomized, Multicenter, Double-Blind, Safety Study Of Ferumoxytol Compared To Ferric Carboxymaltose For The Treatment Of Iron Deficiency Anemia (IDA)

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

This is a Phase III, randomized, double-blind, multicenter, safety study of 1.020 g of IV ferumoxytol, administered as 2 doses of 510 mg each, compared to 1.500 g of IV FCM, administered as 2 doses of 750 mg each for the treatment of iron deficiency anemia.

Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.